Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and ...
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) is one of the world’s leading providers of dialysis products and dialysis services. The company was formed in 1996 through a merger of Fresenius’ dialysis business with National Medical Care, with headquarters in Bad Homburg, Germany. It combines two major parts ...Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) is one of the world’s leading providers of dialysis products and dialysis services. The company was formed in 1996 through a merger of Fresenius’ dialysis business with National Medical Care, with headquarters in Bad Homburg, Germany. It combines two major parts of its value chain—(1) delivery of dialysis treatment and care (service operations) and (2) supply of dialysis-related products (manufacturing and distribution). This integrated approach is designed to support consistent treatment standards for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
From a business perspective, Fresenius Medical Care’s core revenue drivers come from running dialysis clinics and related care settings (outpatient centers and home dialysis support) and from selling dialysis equipment and consumables to clinics and hospitals. Its services include outpatient dialysis therapy, laboratory/diagnostic support, clinical oversight, and coordination of supplies for home patients. In the hospital environment, it also provides dialysis interventions for patients requiring inpatient dialysis support.
On the products side, the company develops and distributes a broad dialysis portfolio: dialyzers (e.g., polysulfone dialyzers), hemodialysis machines, peritoneal dialysis systems and cyclers, concentrates, bloodlines, and water treatment solutions. It also operates in non-dialysis medical devices, including acute cardiopulmonary and apheresis-related products. Additionally, the company’s pharmaceutical and renal medication capabilities focus on developing, acquiring, and in-licensing specialized renal therapies and distributing dialysis drugs and supplies to both dialysis centers and patients’ homes.
In terms of customers and channels, Fresenius Medical Care typically sells directly to dialysis clinics and hospitals, supported by sales teams and partnerships with local distributors, dealers, and agents—while its service footprint (clinic network) creates an internal demand base for many consumables and treatment-related offerings.
Cost structure considerations for this business model usually include (a) clinic and staffing costs (nursing/technician labor, physician-related coverage, facility and equipment), (b) manufacturing and logistics costs for consumables and devices, (c) clinical/regulatory compliance and quality systems, and (d) R&D expenses to improve dialysis therapies, devices, and treatment support. The company’s scale is substantial: it reported managing thousands of outpatient dialysis clinics across roughly 150 countries (as reflected in the provided overview). The company’s workforce is very large—on the order of ~110,000 employees worldwide—placing it firmly in the 100,000+ employee band.
Leadership information from the provided data indicates Helen Giza as CEO (appointed effective December 6, 2022). As a global healthcare provider, Fresenius Medical Care’s strategic “wishes” typically center on sustaining treatment access, improving clinical outcomes, expanding home and outpatient care capabilities, maintaining supply reliability for dialysis consumables, and continuing to innovate across dialysis systems and related renal therapies while meeting strict quality, safety, and regulatory requirements.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$19.6B
+1.5%
+5.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$978.4M
+81.9%
+85.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+25.6%
+4.2%
+5.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+9.3%
+22.6%
+17.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+5.0%
+79.2%
+76.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$1.7B
+0.5%
+1583.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+8.6%
-1.0%
+1497.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
75.6%
+0.1%
+4.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.26x
-9.6%
-11.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Ladies and gentlemen, welcome to the report on Second Quarter 2026 Earnings Release and Conference Call. I am Valentina, the Chorus Call operator. [Operator Instructions] And the conference is being recorded. [Operator Instructions] At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead.
Dominik Heger: Thank you, Valentina. I would like to welcome everyone to our earnings call for the second quarter of 2026. I appreciate your flexibility to join this earlier call. We felt it is more helpful to have the call earlier given that we had to publish earlier than originally planned. I do apologize for the inconvenience, in particular for those of you who are located in a different time zone or those of you who cover another company hosting a call in parallel right now. As always, I start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. The call is scheduled for 1 hour. In order to give everyone the chance to ask questions, we limit the number of questions as always to two. Thank you for making this work. Let me now welcome Helen Giza, CEO and Chair of the Management Board; and Martin Fischer, our Chief Financial Officer. Helen, the floor is yours.
Helen Giza: Thank you, Dominik, and welcome, everyone, and thank you for joining at this earlier time of the day. I will begin my prepared remarks on Slide 4. We continued our strong start to the year, delivering another quarter of highly profitable growth, supported by solid organic revenue development and further improvement in profitability. Operating income growth accelerated to 23%, in line with our planned phasing for the year, and we realized another quarter of margin expansion. This was also supported by the continued execution of our FME25+ transformation program, which delivered EUR 67 million of sustainable savings during the quarter. We also completed our initial EUR 1 billion share buyback program on an accelerated time line and have already launched a second EUR 1 billion program, underscoring our continued focus on disciplined capital allocation and reigniting shareholder returns. With a net leverage ratio of 2.6x, we remain around the lower end of our target corridor and continue to maintain a strong financial position. With that overview, let me turn to the key second quarter highlights across our operating segments on Slide 5. Beginning with Care Delivery. The international markets delivered 0.8% same-market treatment growth. In the U.S., same market treatment growth declined by 0.9%. At the same time, I am genuinely encouraged by the progress we are seeing where it matters most for our patients. Our continued focus on quality and patient care is making a real difference. Missed treatments and mortality improved …
